Physician profile
Weixun Wang
NPI 1265920920
$3,015.54
in general payments reported to CMS, 2019-2025
17 companies · $635 in 2025
The $635 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $18.83 · 2021: $93.58 · 2022: $450 · 2023: $672 · 2024: $799 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $644.39 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $624.83 | 2022-2025 | Precision 1, Eysuvis, Precision7 |
| Allergan, INC. | $274.97 | 2019-2022 | |
| Coopervision INC. | $254.77 | 2021-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $239.30 | 2024-2025 | Xdemvy |
| Abbvie INC. | $206.95 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Novartis Pharmaceuticals Corporation | $172.92 | 2019-2023 | |
| Oyster Point Pharma, INC. | $172.02 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $170.75 | 2024-2025 | |
| Visioneering Technologies, INC. | $77.88 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $47.66 | 2024 | |
| Dompe US, INC. | $30.61 | 2022 | |
| Abb Con-Cise Optical Group LLC | $24.10 | 2023 | Spectacle Lenses, Contact Lens |
| Aerie Pharmaceuticals, INC. | $21.02 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.83 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $17.73 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weixun Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.